Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas - PubMed (original) (raw)
Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas
Lisiane Cervieri Mezzomo et al. Pituitary. 2012 Sep.
Abstract
We aimed at the evaluation of MEG3 and GADD45γ expression in sporadic functioning and clinically non-functioning human pituitary adenomas, morphologically characterized by immunohistochemistry analysis and their association with clinical features. Thirty eight patients who had undergone hypophysectomy at São José Hospital of Irmandade Santa Casa de Misericórdia in Porto Alegre, Brazil, were included in this study. We evaluated tumor-type specific MEG3 and GADD45γ expression by qRT-PCR in the pituitary adenomas, and its association with clinical features, as age, gender and tumor size, obtained from medical records. The patients consisted of 21 males and 17 females and the mean age was 47 ± 14 (mean ± SD), ranging from 18 to 73 years-old. Of these 14 were clinically non-functioning, 10 GH-secreting, 9 PRL-secreting, and 5 ACTH-secreting pituitary adenomas. All samples were macroadenomas, except four ACTH-secreting tumors, which were microadenomas. In summary, MEG3 and GADD45γ expression was significantly lost in most clinically non-functioning adenomas (78 and 92%, respectively). Other assessed pituitary tumor phenotypes expressed both genes at significantly different levels, and, in some cases, with overexpression. There was no significant association between gene expression and the analyzed clinical features. Our results confirm the previous report, which indicated that MEG3 and GADD45γ expression is lost in the majority of human pituitary tumors, mainly in clinically-nonfunctioning adenomas. Functioning tumors had differences of relative expression levels. The two groups of tumors are probably genetically different and may have a different natural history.
Similar articles
- Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.
Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S. Binse I, et al. Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15. Horm Metab Res. 2014. PMID: 25126861 - Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A. Gejman R, et al. J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25. doi: 10.1210/jc.2007-2633. Epub 2008 Jul 15. J Clin Endocrinol Metab. 2008. PMID: 18628527 Free PMC article. - Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.
Cheunsuchon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y, Rice KA, Tessa Hedley-Whyte E, Swearingen B, Klibanski A. Cheunsuchon P, et al. Am J Pathol. 2011 Oct;179(4):2120-30. doi: 10.1016/j.ajpath.2011.07.002. Epub 2011 Aug 24. Am J Pathol. 2011. PMID: 21871428 Free PMC article. - Diagnosis and treatment of pituitary adenomas.
Chanson P, Salenave S. Chanson P, et al. Minerva Endocrinol. 2004 Dec;29(4):241-75. Minerva Endocrinol. 2004. PMID: 15765032 Review. - Pituitary adenomas in childhood and adolescence.
Jackman S, Diamond F. Jackman S, et al. Pediatr Endocrinol Rev. 2013 Jul;10(4):450-9. Pediatr Endocrinol Rev. 2013. PMID: 23957196 Review.
Cited by
- Genetic and Epigenetic Pathogenesis of Acromegaly.
Yamamoto M, Takahashi Y. Yamamoto M, et al. Cancers (Basel). 2022 Aug 10;14(16):3861. doi: 10.3390/cancers14163861. Cancers (Basel). 2022. PMID: 36010855 Free PMC article. Review. - GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer.
Catellani C, Ravegnini G, Sartori C, Angelini S, Street ME. Catellani C, et al. Front Endocrinol (Lausanne). 2021 Aug 16;12:701246. doi: 10.3389/fendo.2021.701246. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34484116 Free PMC article. Review. - lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes.
Wang X, Li X, Wang Z. Wang X, et al. Oncol Rep. 2021 Apr;45(4):40. doi: 10.3892/or.2021.7991. Epub 2021 Mar 2. Oncol Rep. 2021. PMID: 33649837 Free PMC article. - Biomarkers for Liquid Biopsies of Pituitary Neuroendocrine Tumors.
Gossing W, Frohme M, Radke L. Gossing W, et al. Biomedicines. 2020 Jun 2;8(6):148. doi: 10.3390/biomedicines8060148. Biomedicines. 2020. PMID: 32498309 Free PMC article. Review. - Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.
Srirangam Nadhamuni V, Korbonits M. Srirangam Nadhamuni V, et al. Endocr Rev. 2020 Dec 1;41(6):821-46. doi: 10.1210/endrev/bnaa006. Endocr Rev. 2020. PMID: 32201880 Free PMC article. Review.
References
- Ann N Y Acad Sci. 2003 Mar;983:278-85 - PubMed
- Biotechniques. 1993 Sep;15(3):532-4, 536-7 - PubMed
- Annu Rev Pathol. 2009;4:97-126 - PubMed
- Mol Cell Endocrinol. 2010 Sep 15;326(1-2):40-7 - PubMed
- Cancer Res. 2010 Mar 15;70(6):2350-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical